NCT03879057Unknown1 期
Phase I Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surufatinib Combined With JS001 in Patients With Advanced Solid Tumors
Peking University1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2018年12月21日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Maximum tolerated dose
研究概览
简要总结
This is an open-label, phase I study evaluating safety, tolerability, pharmacokinetics and efficacy of Surufatinib combined with the humanized anti-PD-1 antibody JS001 in patients with solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must have read, understood, and provided written informed consent voluntarily. Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol.
- •Male and Female aged between 18 and 75 years are eligible;
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
- •Histologic diagnosis of locally advanced or metastatic unresectable solid tumors (neuroendocrine tumors, liver carcinoma, gastric carcinomas considered with priority);
- •Failed after standard treatment (disease progression or intolerable for toxic side effects) or no effective to treatment;
- •For liver carcinoma with Child-Pugh of grade A and grade B (≤ 7 points);
- •Radiographic evidence of disease rogression by RECIST criteria on or after last anti-cancer therapy within 6 months; If the single lesion previously received radiation, ablation, there must be an imaging identification for disease progression;
- •Predicted survival >=3 months;
- •At least 1 measurable lesion (only 1 measurable lymph node lesion is excluded) (routine CT scan >=20mm, spiral CT scan >=10mm, no prior radiation to measurable lesions);
- •Screening laboratory values must meet the following criteria (within past 14 days): hemoglobin ≥ 9.0 g/dL; neutrophils ≥ 1500 cells/ μL; platelets ≥ 100 x 10^3/ μL; total bilirubin ≤ 1.5 x upper limit of normal (ULN); aspartic transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic metastasis; serum creatinine ≤1╳ULN, creatinine clearance >50ml/min (CockcroftGault equation) PT/INR, aPTT≤1.5 x ULN;
- •Males or female of childbearing potential must: agree to use using a reliable form of contraception (eg, oral contraceptives, intrauterine device, control sex desire, double barrier method of condom and spermicidal) during the treatment period and for at least 12 months after the last dose of study drug.
排除标准
- •The toxicity associated with previous anti-tumor treatment has not recovered to ≤CTCAE1, except for peripheral neurotoxicity and alopecia ≤CTCAE2 caused by oxaliplatin;
- •Had other malignant tumors in the past 5 years (except for basal cell carcinoma or squamous cell carcinoma, cervical carcinoma in situ that have been effectively controlled);
- •Evidence with active CNS disease;
- •Prior treatment with chemotherapy, biological immunotherapy, targeted therapy, Chinese herbal medicine within 2 weeks.
- •Prior treatment with radical radiation within 4 weeks
- •Prior treatment with antiPD1/PDL1/PDL2/CTLA-4 antibody or Sulfatinib;
- •Prior treatment with corticosteroids (dose > 10 mg/day prednisone or other hormones) or other immunosuppressive agents within 2 weeks, nasal or inhalation in allowed (dose > 10 mg/day prednisone or other hormones).
- •Patients with any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, such as hypophysitis, pneumonia, colitis, hepatitis, nephritis, hyperthyroidism or hypothyroidism;
- •Prior live vaccine therapy within past 4 weeks;
- •Prior major surgery within past 4 weeks (diagnostic surgery excluded);
- •Uncontrolled malignant pleural effusion, ascites or pericardial effusion;
- •Hypertension that is not controlled by the drug, and is defined as: SBP≥140 mmHg and/or DBP≥90 mmHg;
- •The patient currently has disease or condition that affects the absorption of the drug, or the patient cannot be administered orally;
- •Received a potent inducer or inhibitor of CYP3A4 within 2 weeks, or continue receiving these drugs during the study;
- •Digestive tract disease such as gastric and duodenal active ulcer, ulcerative colitis or unresected tumor, or other conditions determined by the investigator that may cause gastrointestinal bleeding and perforation;
- •Evidence of bleeding tendency or history within 2 months, or thromboembolic event (including a stroke event and/or a transient ischemic attack) occurred within 12 month;
- •Severe, uncontrolled medical condition that would affect patients' compliance or obscure the interpretation of toxicity determination or adverse events, including active severe infection, uncontrolled diabetes, angiocardiopathy (heart failure > class II NYHA, LVEF <50%, myocardial infarction, unstable arrhythmia or unstable angina within past 6 months, cerebral infarction within past 3 months) or pulmonary disease ( interstitial pneumonia, obstructive pulmonary disease or symptomatic bronchospasm);
- •Clinically significant severe electrolyte abnormality judged by investigator ;
- •Active infection or unexplained fever during the screening period (temperature >38.5C)
- •History with tuberculosis who are receiving or have received anti-TB treatment within 1 year.
- •Pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-associated pneumonia, severe impaired lung function, etc; Radiation pneumonitis in the radiotherapy area is allowed;
- •Positive tests for HIV, HCV, HBsAg or HBcAb with positive test for HBV DNA (>2000IU/ml);
- •Prior antitumor therapy (including corticosteroids and immunotherapy) or participation in other clinical trials within past 4 weeks, or have not recovered from toxicities since the last treatment;
- •Pregnant or nursing;
- •Hypersensitivity to Sulfatinib or recombinant humanized antiPD1 monoclonal Ab;
- •Underlying medical condition that, in the Investigator's opinion, would increase the risks of study drug administration or obscure the interpretation of toxicity determination or adverse events.
研究组 & 干预措施
Surufatinib 200mg/JS001 240mg
Experimental
Surufatinib at a dose of 200mg Qd, with humanized anti-PD-1 monoclonal antibody（JS001） injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
干预措施: Surufatinib/humanized anti-PD-1 monoclonal antibody (Drug)
Surufatinib 300mg/JS001 240mg
Experimental
Surufatinib at a dose of 300mg Qd, with humanized anti-PD-1 monoclonal antibody（JS001) injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
干预措施: Surufatinib/humanized anti-PD-1 monoclonal antibody (Drug)
结局指标
主要结局
Maximum tolerated dose
时间窗: 4 week
tolerability during the treatment of first cycle
adverse events
时间窗: 1 year
Safety of participants followed for the duration of hospital stay, an expected average of 1 week
次要结局
- Objective response rate(From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months)
- time to treatment failure(TTF)(1 month)
- Maximum Plasma Concentration (Cmax)(8 days)
- Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf))(8 days)
研究者
Shen Lin
MD, Professor, Chief of Department of GI Oncology, Peking University Cancer Hospital
Peking University
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid TumorsSolid TumorsNCT06001684Imbioray (Hangzhou) Biomedicine Co., Ltd.19
Unknown
1 期
Clinical Study of JS007 in Patients With Advanced Solid TumorsPatients With Advanced Solid TumorsNCT05049265Shanghai Junshi Bioscience Co., Ltd.42
已完成
1 期
Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid MalignanciesAdvanced Solid MalignanciesNCT03394144AstraZeneca11
已完成
1 期
A Phase I Study of MEDI9447 (Oleclumab) in Japanese PatientsAdvanced Solid MalignanciesNCT03736473AstraZeneca6
已完成
1 期
An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid MalignanciesAdvanced Solid MalignanciesNCT05469919AstraZeneca12